Chondroitin sulfate proteoglycan biosynthetic process

Across TCGA pan-cancer cohorts, RNA activity of the Chondroitin sulfate proteoglycan biosynthetic process pathway is associated with patient survival in 22 of 34 cancer lineages. Pathway activity is summarized from the expression of its 24 member genes.

The strongest signal is observed in mesothelioma (MESO), where higher Chondroitin sulfate proteoglycan biosynthetic process pathway activity is associated with poorer overall survival. In most high-consensus cancer types, elevated pathway activity shows an unfavorable survival association, although some cancer types, such as UVM and ESCA, show the opposite pattern, with higher activity associated with better survival.

MESO, BLCA, and STAD are the cancer lineages in which this pathway most reproducibly stratifies patient survival.

Pathway-activity survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 represent the survival AUCs for the high- and low-pathway-activity groups, respectively. The group with the lower AUC is interpreted as having poorer survival. The reported p-values are derived from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.259	0.514	<.001	111	view →
BLCA	DFS	Median	All	0.444	0.561	.001	88	view →
STAD	OS	Tertile	All	0.300	0.504	.001	79	view →
UVM	DFS	Median	All	0.814	0.446	<.001	45	view →
ESCA	DFS	Median	III,IV	0.559	0.317	.004	35	view →
LIHC	DFS	Quartile	All	0.430	0.611	.001	32	view →
BRCA	DFS	Quartile	All	0.446	0.601	.008	27	view →
COAD	DFS	Quartile	All	0.298	0.584	.002	25	view →
SKCM	OS	Quartile	II,III,IV	0.839	0.588	.003	24	view →
SCLC	DFS	Median	III,IV	0.217	0.552	.001	22	view →
CHOL	OS	Median	All	0.793	0.463	.018	21	view →
OV	OS	Median	All	0.786	0.883	.001	20	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

GO:0050650–MESO (OS)

Open the MESO breakdown →